Serum amyloid A may be associated with hydatidiform mole

Abstract

Hydatidiform mole (HM) is a gestational trophoblastic disease. Potential risk factors are advanced maternal age, reproductive factors, oral contraceptive use, history of gestational trophoblastic disease, oxidative stress, and other environmental factors. Serum amyloid A (SAA) protein has an important role in acute phase response but also associated with pathologic fibril formation in chronic inflammation. The aim of the current study is to determine the relationship between maternal SAA levels in patients with both complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM), and to examine possible role in the disease in pathogenesis. Fifty healthy pregnant women in the first trimester of pregnancy with completely normal pregnancy follow-up, and 50 patients who were diagnosed with HM, who were also in the first trimester of pregnancy included to the study. There was no difference between patients and control group according to body mass index (BMI), gravidity, parity, number of living children, number of miscarriage, level of blood TSH, and hemoglobin level between two groups. SAA levels in patients with HM were significantly higher than those in healthy controls. This may be an important underexplored pathway mediating the relationship between oxidative stress and abnormal placental proliferation.

Keywords

• Hydatidiform mole
• molar pregnancy
• Inflammation
• serum amyloid A

References

1. 1. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obset Gynecol. 2010;203:531–539.
2. 2. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morpho- logic correlations. Am J Obstet Gynecol. 1978;131:665–671.
3. 3. Newlands ES, Paradinas FJ, Fisher RA . Recent advances in gestational trophoblastic disease. Hematol Oncol Clin North Am. 1999 Feb;13(1):225-44, x.
4. 4. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003;4:670–678.
5. 5. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005;3:28.
6. 6. Gupta S, Agarwal A, Banerjee J, Alvarez JG. The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review. Obstet Gynecol Surv. 2007 May;62(5):335-47; quiz 353-4.
7. 7. Harma M, Harma M. Defective placentation and resultant oxidative stress play a similar role in complete hydatidiform mole to that in preeclampsia and early pregnancy loss. Med Hypotheses. 2006;66(1):100-2. Epub 2005 Sep 19.
8. 8. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009; 14: 187–196.

9. 9. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol. 2000 Jan; 7:64–69.
10. 10. Kovacevic A, Hammer A, Sundl M, Pfister B, Hrzenjak A, et al. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett. 2006;580:161–167.
11. 11. Uckan K, Sahin HG. Serum amyloid A, procalcitonin, highly sensitive C reactive protein and tumor necrosis factor alpha levels and acute inflammatory response in patients with hemolysis, elevated liver enzymes, low platelet count (HELLP) and eclampsia. J Obstet Gynaecol Res. 2018 Mar;44(3):440-447.
12. 12. Engin-Ustün Y, Ustün Y, Karabulut AB, Ozkaplan E, Meydanli MM, Kafkasli A. Serum amyloid A levels are increased in pre-eclampsia. Gynecol Obstet Invest. 2007;64(2):117-20.
13. 13. Ibrahim MI, Ramy AR, Abdelhamid AS, Ellaithy MI, Omar A, Harara RM, et al. Maternal serum amyloid A level as a novel marker of primary unexplained recurrent early pregnancy loss. Int J Gynaecol Obstet. 2017 Mar;136(3):298-303.
14. 14. Harma M, Harma M, Kocyigit A. Comparison of protein carbonyl and total plasma thiol concentrations in patients with complete hydatidiform mole with those in healthy pregnant women. Acta Obstet Gynecol Scand. 2004;83((9)):857–60.
15. 15. Ferraz L, Ramos CAB, Braga A, Velarde LGC, Elias KM, et al. Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020;75:e1724.
16. 16. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55–74.
17. 17. Lash GE, Quenby S, Burton GJ, Nakashima A, Kamat BR, Ray J, et al. Gestational diseases – a workshop report. Placenta 2008;29 (Suppl. A):S92–4.
18. 18. Sharp AN, Heazell AE, Crocker IP, Mor G. Placental apoptosis in health and disease. Am J Reprod Immunol. 2010;64:159–69.
19. 19. Ferraz L, Ramos CAB, Braga A, Velarde LGC, Elias KM, Horowitz NS, et al. Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020;75:e1724.
20. 20. Incebiyik A, Vural M, Camuzcuoglu H, Taskin A, Camuzcuoglu A, Hilali NG, et al. Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole? Wien Klin Wochenschr. 2016 Dec;128(Suppl 8):566-571.
21. 21. Koseoglu SB, Guzel AI, Deveer R, et al. Maternal serum amyloid A levels in pregnancies complicated with preterm prelabour rupture of membranes. Ginekol Pol 2014;85:516-520.
22. 22. Sandri S, Urban BA, Fernandes I, et al. Serum amyloid A in the placenta and its role in trophoblast invasion. PLoS ONE. 2014;9:e90881.
23. 23. Michaeli A, Finci Yeheskel Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S. Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun. 2008 Apr 4;368(2):368–373.
24. 24. Verit FF, Hilali NG. Increased insulin resistance and C-reactive protein in women with complete hydatidiform mole. Gynecol Endocrinol. 2011 Oct;27(10):840-3.
25. 25. Rossi L, Martin BM, Hortin GL, et al: Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 6:709-720, 2006.
26. 26. Yamada T. Serum amyloid A (SAA): A concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381-388, 1999.